DISEASE INDICATIONS: Risk of cardiovascular events, Hypercholesterolemia

MANUFACTURER: Amgen Inc.

USAGE: Subcutaneous

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Health Canada

Pharmaceuticals and Medical Devices Agency (PMDA)

Repatha (evolocumab) is a medication that reduces the risk of cardiovascular disease through decreasing low-density lipoprotein (LDL) cholesterol levels by targeting and inhibiting PCSK9. It is administered subcutaneously once every two weeks or once a month and should be stored in a refrigerator. Repatha is used as an adjunct to diet and other lipid-lowering therapies.